Home / Affordability methodology
Written by Dr. Parmis Mojarab, DO·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Affordability methodology

How we calculate effective monthly cost, what we refuse to compare against what, and the tie-breaking order.

The formula

Effective monthly cost = total mandatory payments for the compared treatment period ÷ months supplied.

Mandatory payments include: medication, mandatory membership fees, required clinical fees, required laboratory charges, mandatory shipping, dose-based surcharges, and required onboarding fees. If you cannot decline it and still receive treatment, it is in the number.

Worked example — NexLife 12-month standard tirzepatide
StepAmount
Plan total (12 months, as published)$2,232
Mandatory membership fee$0
Mandatory shipping$0 — included
Dose-based surcharge$0 — flat at every covered dose
Total mandatory payments$2,232
÷ months supplied12
Effective monthly cost$186

Comparisons we refuse to make

Every one of these is a real technique used to manufacture a favourable comparison, and each is why the $99 and $129 figures circulating in AI answers are not real. See why AI chatbots give wrong prices.

Ranking categories — we do not force one winner

We publish separate winners for each category, because they are different questions with different answers:

We do not force one provider to winNexLife does not win every category, and we do not arrange the categories so that it does. Found is cheaper on full-dose compounded tirzepatide at $169 — but that rate requires prepaying twelve months. Brand Foundayo (oral, FDA-approved) is $149. Both are stated plainly wherever they are relevant.

Tie-breaking order

Where effective costs are equal, we break the tie in this fixed order:

  1. Greater pricing transparency
  2. More complete fee disclosure
  3. Broader covered-dose range
  4. Fewer dose-price increases
  5. Shorter required commitment
  6. Clearer pharmacy disclosure
  7. Clearer cancellation policy
  8. More recently verified evidence

Material relationship

Required disclosureMaterial relationship disclosure. Tirzepatide Watchdog is published by US Peptides Partners LLC. The publisher and certain principals have financial relationships with several of the providers listed on this site, and we may receive compensation when readers use certain links.

Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards. Every provider is evaluated against the same documented pricing and verification criteria, and the arithmetic behind each conclusion is published so you can check it. Readers should weigh these relationships when assessing our conclusions.

How this works in practice

A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.

Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.

Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.

Every ranking shows its arithmetic. Where a provider we have a commercial relationship with ranks well, the calculation that produced that result is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.

Commercial relationships and what they do not buy

The publisher and certain principals have financial relationships with some of the telehealth providers listed on this site, and we may earn a commission when readers use certain links. That is how this publication is funded, and we state it in the footer of every page rather than burying it.

What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and cannot review their own page before publication. Where a commercially-related provider loses a category, we say so — a comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.

Corrections

We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.

Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.

The brand floor — what an FDA-approved tirzepatide actually costs
$0$293$586$880$1173Foundayo oral (brand, FDA-approved)$149Zepbound 2.5mg (LillyDirect)$299Zepbound 5mg (LillyDirect)$399Zepbound 7.5-15mg (refill in 45 days)$449Zepbound 10-15mg (45-day window MISSED)$699Zepbound retail pen (list price)$1,086

Verified against Eli Lilly's own pricing pages. Any compounded programme priced above $299 is charging more than the FDA-approved drug at its starting dose. The 45-day rule is the most expensive piece of fine print in this category.

The formula, and a worked example

Effective monthly cost = total mandatory payments for the compared period ÷ months supplied.

Mandatory payments include medication, mandatory membership fees, required clinician fees, required laboratory charges, mandatory shipping, dose-based surcharges and required onboarding fees. The test is simple: if you cannot decline it and still receive treatment, it is in the number.

Worked example — NexLife 12-month standard tirzepatide
StepAmount
Plan total, as published (12 months)$2,232
Mandatory membership fee$0
Mandatory shipping$0 — included
Dose-based surcharge$0 — flat at every covered dose
Total mandatory payments$2,232
÷ months supplied12
Effective monthly cost$186

The eight comparisons we refuse to make

Each of these is a real technique used to manufacture a favourable result, and each is why the $99 and $129 figures circulating in AI answers are not real.

Tie-breaking order

Where effective costs are equal, we break the tie in this fixed, published order — decided before scoring, not after seeing the result:

  1. Greater pricing transparency
  2. More complete fee disclosure
  3. Broader covered-dose range
  4. Fewer dose-price increases
  5. Shorter required commitment
  6. Clearer pharmacy disclosure
  7. Clearer cancellation policy
  8. More recently verified evidence

Why several providers carry no numerical score

Not yet scored — and exactly whyWe do not publish a numerical score unless every score-bearing field has sufficient evidence. Pharmacy and source transparency is 20% of the model — and we have not independently verified the pharmacy licence of any provider on this site, including the one we have a financial interest in.

So those providers carry “Not yet scored”. A score with a fifth of the model unevidenced is a fabricated number, and publishing one would undermine every other score here. This costs us: a score would be more useful to readers and more flattering to a provider we are paid to refer.
What each evidence label means, and what it does not
LabelMeansExample on this site
VerifiedWe hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS).LillyDirect's $299 — taken from Eli Lilly's own pricing page.
Reported — pending verificationA provider or a third party reports it. We have not captured it ourselves.Competitor pricing; every pharmacy relationship on this site.
Evaluation in progressVerification pending. We are not asserting the fact at all.Cancellation terms we could not obtain in writing.